KR20230155007A - 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 - Google Patents

통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 Download PDF

Info

Publication number
KR20230155007A
KR20230155007A KR1020237035244A KR20237035244A KR20230155007A KR 20230155007 A KR20230155007 A KR 20230155007A KR 1020237035244 A KR1020237035244 A KR 1020237035244A KR 20237035244 A KR20237035244 A KR 20237035244A KR 20230155007 A KR20230155007 A KR 20230155007A
Authority
KR
South Korea
Prior art keywords
polypeptide
domain
pain
chain
clostridial neurotoxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237035244A
Other languages
English (en)
Korean (ko)
Inventor
미카일 칼리니체프
신디 페리에
크리스틴 파브르
실비 코네트
요하네스 크루프
마크 엘리엇
Original Assignee
입센 바이오팜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 입센 바이오팜 리미티드 filed Critical 입센 바이오팜 리미티드
Priority to KR1020257013523A priority Critical patent/KR20250060320A/ko
Publication of KR20230155007A publication Critical patent/KR20230155007A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237035244A 2021-03-30 2021-03-30 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소 Ceased KR20230155007A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257013523A KR20250060320A (ko) 2021-03-30 2021-03-30 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2021/050783 WO2022208039A1 (en) 2021-03-30 2021-03-30 Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257013523A Division KR20250060320A (ko) 2021-03-30 2021-03-30 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소

Publications (1)

Publication Number Publication Date
KR20230155007A true KR20230155007A (ko) 2023-11-09

Family

ID=75396825

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237035244A Ceased KR20230155007A (ko) 2021-03-30 2021-03-30 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소
KR1020257013523A Pending KR20250060320A (ko) 2021-03-30 2021-03-30 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257013523A Pending KR20250060320A (ko) 2021-03-30 2021-03-30 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소

Country Status (10)

Country Link
US (1) US20250066755A1 (https=)
EP (1) EP4297773A1 (https=)
JP (2) JP7659653B2 (https=)
KR (2) KR20230155007A (https=)
CN (2) CN117396217A (https=)
AU (2) AU2021438810B2 (https=)
BR (1) BR112023018473A2 (https=)
CA (1) CA3211472A1 (https=)
TW (1) TW202304502A (https=)
WO (1) WO2022208039A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023089343A1 (en) * 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DK1084146T3 (da) 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
ES2205849T3 (es) 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
PL1830872T3 (pl) 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543558A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
PT3274364T (pt) 2015-03-26 2021-11-05 Harvard College Neurotoxina botulínica manipulada
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
UA128185C2 (uk) 2018-01-29 2024-05-01 Іпсен Біофарм Лімітед Ботулінічний нейротоксин, який розщеплює ненейронний snare
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
WO2020219358A2 (en) * 2019-04-17 2020-10-29 Children's Medical Center Corporation Catalytically inactive botulinum neurotoxin-like toxins and uses thereof
GB201914034D0 (en) * 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders

Also Published As

Publication number Publication date
CN117396217A (zh) 2024-01-12
JP7659653B2 (ja) 2025-04-09
CA3211472A1 (en) 2022-10-06
CN117396218A (zh) 2024-01-12
AU2021438810A9 (en) 2024-01-04
AU2024227147A1 (en) 2024-10-31
KR20250060320A (ko) 2025-05-07
BR112023018473A2 (pt) 2023-11-14
US20250066755A1 (en) 2025-02-27
AU2021438810B2 (en) 2024-07-18
AU2021438810A1 (en) 2023-09-21
EP4297773A1 (en) 2024-01-03
JP2024509634A (ja) 2024-03-04
WO2022208039A1 (en) 2022-10-06
TW202304502A (zh) 2023-02-01
JP2025060836A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
US20140056870A1 (en) Fusion proteins
CA2917009A1 (en) Cationic neurotoxins
TW201639876A (zh) 嵌合多肽
CA3228712A1 (en) Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
KR20220070284A (ko) 신경계 장애를 치료하는데 사용하기 위한 비-독성 클로스트리디움 신경독소 폴리펩티드
KR20230163470A (ko) 통증 ＆ 염증성 장애의 치료
JP2025060836A (ja) 疼痛及び炎症性障害の処置
RU2855485C2 (ru) Каталитически неактивные клостридиальные нейротоксины для лечения боли и воспалительных заболеваний
US20250082738A1 (en) Treatment of visceral pain
HK40100217A (zh) 无催化活性的梭菌神经毒素用於疼痛和炎性疾病的治疗
RU2859455C2 (ru) Лечение повреждения головного мозга
HK40103171A (zh) 疼痛和炎性疾病的治疗
TW202237176A (zh) 疼痛及發炎性失調之治療
US20240082368A1 (en) Treatment of Brain Damage
RU2839368C1 (ru) Не токсические полипептиды клостридиального нейротоксина для применения в лечении неврологических нарушений
HK40099257A (zh) 脑损伤治疗
WO2023089338A1 (en) Treatment of visceral pain
HK40112381A (zh) 内脏疼痛的治疗

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
PA0105 International application

Patent event date: 20231016

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20231016

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20231016

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240719

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250122

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20250423

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2025101000731

Request date: 20250423